TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景

TST003

BMP Antagonist (FIC)
Target:
BMP Antagonist (FIC)
Indication:
Solid Tumors
Project Status:
Preclinical

TST003 is a high affinity humanized monoclonal antibody targeting a regulatory protein that is highly expressed by stromal cells in diverse human carcinomas, especially in esophageal cancer, pancreatic cancer, gastric cancer, colon cancer, lung cancer, breast cancer and prostate cancer, among others. TST003 has demonstrated significant anti-tumor activities both in vitro and in vivo in preclinical studies. TST003 has the potential to become a novel cancer treatment, either as monotherapy or in combination with immune checkpoint inhibitor and/or other anti-tumor agents.


t003.jpg

PNAS | October 3, 2006 | vol. 103 | no. 40 | 14842-14847

TOP